Antimicrobial Therapy in Intensive Care Unit

doi:10.3390/books978-3-0365-6768-6

Download Url(s)

https://mdpi.com/books/pdfview/book/6959

Contributor(s)

Paramythiotou, Elizabeth (editor)

Routsi, Christina (editor)

Andremont, Antoine (editor)

Language

English

Show full item record

Abstract

This reprint is an excellent collection of articles that deal with difficult-to-treat infections in the ICU environment. Multiresistant bacteria and fungi create severe treatment problems to the physician charged with their care. We hope that this book will help everyday dilemmas and add useful information on difficult topics.

URI

https://directory.doabooks.org/handle/20.500.12854/98906

Keywords

Acinetobacter; pandrug-resistant; antimicrobial combinations; synergy; renal replacement therapy; Monte Carlo simulation; antibiotics; pharmacokinetics; pharmacodynamics; microbiome; probiotics; intensive care unit; dysbiosis; ventilator-associated pneumonia; extracorporeal membrane oxygenation; ECMO; critical illness; antibiotic choices; HAP; VAP; colonization; antibiotic pressure; bloodstream infection; bacteraemia; sepsis; septic shock; empirical; probabilistic antibiotics; source control; de-escalation; ICU; intensive care; antimicrobial stewardship; COVID-19; procalcitonin; C-reactive protein; presepsin; infection; biomarker; guided antimicrobial therapy; APACHE II score; bacteremia; broth microdilution; colistin; colistin-resistant; Gram-negative; mortality; SOFA score; candidemia; incidence; epidemiology; Candida species; non-albicans Candida species; fluconazole resistance; critically ill; beta-lactam antibiotics; Acinetobacter baumannii; antibiotic optimisation; antibiotic stewardship (AMS); aspiration pneumonia; hospital-acquired pneumonia (HAP); multidrug-resistance (MDR); non-fermentative Gram-negative bacilli (GNB); polymicrobial; pneumonia resolution; ventilator-associated pneumonia (VAP); carbapenem-resistant A. baumannii (CRAb); infection control; antimicrobial agents; carbapenems; antibiotic resistance; clinical pharmacy services; Klebsiella pneumoniae; Pseudomonas aeruginosa; salvage treatment; double carbapenem; newer β-lactam-β-lactamase inhibitors; cefiderocol; eravacycline; SARS-CoV-2 infection; mechanical ventilation; risk factors; blood stream infection; defined daily dose; antibiotics utilization; empiric; n/a